JP2012526855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526855A5 JP2012526855A5 JP2012511072A JP2012511072A JP2012526855A5 JP 2012526855 A5 JP2012526855 A5 JP 2012526855A5 JP 2012511072 A JP2012511072 A JP 2012511072A JP 2012511072 A JP2012511072 A JP 2012511072A JP 2012526855 A5 JP2012526855 A5 JP 2012526855A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- amount
- carrier
- mannitol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17967809P | 2009-05-19 | 2009-05-19 | |
| US61/179,678 | 2009-05-19 | ||
| PCT/US2010/035357 WO2010135396A2 (en) | 2009-05-19 | 2010-05-19 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526855A JP2012526855A (ja) | 2012-11-01 |
| JP2012526855A5 true JP2012526855A5 (enExample) | 2013-04-04 |
| JP5752677B2 JP5752677B2 (ja) | 2015-07-22 |
Family
ID=42635489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511072A Active JP5752677B2 (ja) | 2009-05-19 | 2010-05-19 | ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオンの製剤 |
Country Status (34)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| EP3351240B1 (en) | 2009-05-19 | 2019-04-10 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| US9968627B2 (en) | 2013-03-26 | 2018-05-15 | Celgene Corporation | Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof |
| EP2981262A1 (en) * | 2013-04-02 | 2016-02-10 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| NZ631364A (en) * | 2013-08-08 | 2017-09-29 | Array Biopharma Inc | Filanesib combined with pomalidomide displays enhanced anti-tumor activity |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| CN104523692A (zh) * | 2014-12-16 | 2015-04-22 | 南京艾德凯腾生物医药有限责任公司 | 一种泊马度胺复合物及其制备方法 |
| DK3313528T3 (da) | 2015-06-29 | 2021-09-20 | Bristol Myers Squibb Co | Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer |
| CN105213392A (zh) * | 2015-09-29 | 2016-01-06 | 浙江大学 | 泊马度胺在制备减轻多发性硬化症的药物中的应用 |
| WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
| WO2018013689A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| EP3493791A1 (en) * | 2016-08-02 | 2019-06-12 | Synthon B.V. | Pharmaceutical composition comprising pomalidomide |
| US10966971B2 (en) | 2017-02-18 | 2021-04-06 | Natco Pharma Limited | Pharmaceutical compositions of pomalidomide |
| US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
| CA3075716A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN107982216A (zh) * | 2017-12-08 | 2018-05-04 | 佛山市弘泰药物研发有限公司 | 一种泊马度胺自微乳制剂及其制备方法 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| EP3545949A1 (en) * | 2018-03-29 | 2019-10-02 | Midas Pharma GmbH | Oral dosage forms comprising pomalidomide crystalline form a |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| WO2021133874A1 (en) * | 2019-12-23 | 2021-07-01 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| BR112022020897A2 (pt) | 2020-04-15 | 2022-11-29 | Tecnimede Sociedade Tecnico Medicinal Sa | Forma de dosagem oral sólida compreendendo pomalidomida. |
| EP3900701A1 (en) | 2020-04-22 | 2021-10-27 | Lotus Pharmaceutical Co., Ltd. | Composition of pomalidomide for oral dosage form |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| WO2023062647A1 (en) * | 2021-10-12 | 2023-04-20 | Reliance Life Sciences Pvt.Ltd. | Pomalidomide formulation |
| EP4233849A1 (en) | 2022-02-25 | 2023-08-30 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising pomalidomide |
| CN118108655B (zh) * | 2024-04-23 | 2024-06-28 | 四川大学华西医院 | 一类异吲哚啉-1,3-二酮衍生物、其制备方法、其用途和含该衍生物的药物组合物 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US555939A (en) * | 1896-03-10 | Device for opening sealed packages | ||
| US3145146A (en) | 1961-10-31 | 1964-08-18 | Warner Lambert Pharmaceutical | Modified mannitol for pharmaceutical tablets |
| US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
| JPS601128A (ja) | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | 作用持続型セフアクロル製剤 |
| US4551177A (en) | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
| JPS6396126A (ja) | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
| US5974203A (en) | 1988-04-11 | 1999-10-26 | Canon Kabushiki Kaisha | Pattern recognition communication apparatus for transmitting and receiving image data |
| AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| US5594637A (en) | 1993-05-26 | 1997-01-14 | Base Ten Systems, Inc. | System and method for assessing medical risk |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| JPH10508131A (ja) | 1994-10-28 | 1998-08-04 | アドバンスド・ヘルス・メド・イー・システムズ コーポレーション | 処方箋管理システム |
| US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
| US5619991A (en) | 1995-04-26 | 1997-04-15 | Lucent Technologies Inc. | Delivery of medical services using electronic data communications |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| JPH0977669A (ja) | 1995-09-19 | 1997-03-25 | Takeda Chem Ind Ltd | ビタミンｂ群顆粒品の組成物およびその製造方法 |
| US5832449A (en) | 1995-11-13 | 1998-11-03 | Cunningham; David W. | Method and system for dispensing, tracking and managing pharmaceutical trial products |
| US6063026A (en) | 1995-12-07 | 2000-05-16 | Carbon Based Corporation | Medical diagnostic analysis system |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| US5924074A (en) | 1996-09-27 | 1999-07-13 | Azron Incorporated | Electronic medical records system |
| US6131090A (en) | 1997-03-04 | 2000-10-10 | Pitney Bowes Inc. | Method and system for providing controlled access to information stored on a portable recording medium |
| WO1999010829A1 (en) | 1997-08-22 | 1999-03-04 | Deka Products Limited Partnership | Health care system and method for physician order entry |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| CA2350304A1 (en) | 1998-11-10 | 2000-05-18 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing l-dopa ethyl ester |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| GB9904585D0 (en) | 1999-02-26 | 1999-04-21 | Gemini Research Limited | Clinical and diagnostic database |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US6202923B1 (en) | 1999-08-23 | 2001-03-20 | Innovation Associates, Inc. | Automated pharmacy |
| US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
| JP5336686B2 (ja) | 1999-11-24 | 2013-11-06 | スージェン， インク． | 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方 |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| CA2430669C (en) | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US7125565B2 (en) | 2000-12-01 | 2006-10-24 | Kyowa Hakko Kogyo Co., Ltd. | Composition improved in the solubility or oral absorbability |
| US20020128228A1 (en) | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
| US20040190609A1 (en) | 2001-11-09 | 2004-09-30 | Yasuhiko Watanabe | Moving picture coding method and apparatus |
| JP4027693B2 (ja) | 2002-03-20 | 2007-12-26 | トリニティ工業株式会社 | 塗料送給装置及びバルブユニット |
| CN1658848A (zh) * | 2002-04-12 | 2005-08-24 | 细胞基因公司 | 血管生成调节剂的鉴定方法,由此发现的化合物和使用该化合物的治疗方法 |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US7230012B2 (en) | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| US20040191298A1 (en) | 2003-03-26 | 2004-09-30 | Fredrik Nicklasson | New formulations and use thereof |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2005051350A2 (en) | 2003-10-28 | 2005-06-09 | Torrent Pharmaceuticals Limited | Water dispersible tablet |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| BRPI0417186A (pt) | 2003-12-02 | 2007-03-06 | Celgene Corp | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| GB0400993D0 (en) | 2004-01-16 | 2004-02-18 | Norton Healthcare Ltd | Stable gabapentin compositions |
| AU2005226649B2 (en) | 2004-03-22 | 2010-04-29 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| BRPI0510110A (pt) | 2004-04-23 | 2007-09-25 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
| WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| CN101102771A (zh) | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
| MX2007011119A (es) | 2005-03-15 | 2007-11-14 | Lupin Ltd | Composiciones farmaceuticas de amlodipino y benazepril. |
| KR101435199B1 (ko) | 2005-05-18 | 2014-08-28 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 드록시도파를 함유하는 안정한 정제 |
| SI1884242T1 (sl) | 2005-05-26 | 2013-07-31 | Dainippon Sumitomo Pharma Co., Ltd. | Farmacevtski sestavek, ki vsebuje lurazidon |
| JP2007028086A (ja) | 2005-07-14 | 2007-02-01 | Funai Electric Co Ltd | リモコン装置 |
| PL1928492T3 (pl) | 2005-09-01 | 2011-09-30 | Celgene Corp | Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby |
| US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| CN101389330A (zh) * | 2005-12-29 | 2009-03-18 | 细胞基因公司 | 采用氨基异吲哚啉化合物治疗皮肤狼疮的方法 |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| CN101977603A (zh) | 2008-01-29 | 2011-02-16 | 细胞基因公司 | 使用免疫调节化合物来调节cd59水平的方法 |
| EP3351240B1 (en) | 2009-05-19 | 2019-04-10 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
-
2010
- 2010-05-19 EP EP18160247.5A patent/EP3351240B1/en not_active Revoked
- 2010-05-19 NZ NZ594557A patent/NZ594557A/xx unknown
- 2010-05-19 RU RU2011134499/15A patent/RU2479307C1/ru active
- 2010-05-19 EP EP17151178.5A patent/EP3199149A1/en not_active Withdrawn
- 2010-05-19 PT PT107201071T patent/PT2391355T/pt unknown
- 2010-05-19 ES ES18160247T patent/ES2728776T3/es active Active
- 2010-05-19 MX MX2014014182A patent/MX342330B/es unknown
- 2010-05-19 SM SM20170097T patent/SMT201700097T1/it unknown
- 2010-05-19 HR HRP20170179TT patent/HRP20170179T1/hr unknown
- 2010-05-19 US US12/783,390 patent/US8828427B2/en active Active
- 2010-05-19 ES ES10720107.1T patent/ES2615511T3/es active Active
- 2010-05-19 EP EP25159069.1A patent/EP4582105A3/en active Pending
- 2010-05-19 PT PT18160247T patent/PT3351240T/pt unknown
- 2010-05-19 LT LTEP18160247.5T patent/LT3351240T/lt unknown
- 2010-05-19 UA UAA201110180A patent/UA102582C2/ru unknown
- 2010-05-19 CN CN201080008733XA patent/CN102333525A/zh active Pending
- 2010-05-19 MX MX2011008554A patent/MX2011008554A/es active IP Right Grant
- 2010-05-19 CN CN201610012040.7A patent/CN105640918A/zh active Pending
- 2010-05-19 PL PL18160247T patent/PL3351240T3/pl unknown
- 2010-05-19 AU AU2010249615A patent/AU2010249615B2/en active Active
- 2010-05-19 SG SG2011059839A patent/SG174137A1/en unknown
- 2010-05-19 SI SI201031406A patent/SI2391355T1/sl unknown
- 2010-05-19 PL PL10720107T patent/PL2391355T3/pl unknown
- 2010-05-19 CA CA2752550A patent/CA2752550C/en active Active
- 2010-05-19 HU HUE18160247A patent/HUE043862T2/hu unknown
- 2010-05-19 HU HUE10720107A patent/HUE033115T2/en unknown
- 2010-05-19 LT LTEP10720107.1T patent/LT2391355T/lt unknown
- 2010-05-19 DK DK10720107.1T patent/DK2391355T3/en active
- 2010-05-19 PE PE2011001611A patent/PE20120654A1/es active IP Right Grant
- 2010-05-19 DK DK18160247.5T patent/DK3351240T3/da active
- 2010-05-19 KR KR1020117020477A patent/KR101381060B1/ko active Active
- 2010-05-19 BR BRPI1007855-0A patent/BRPI1007855B1/pt active IP Right Grant
- 2010-05-19 TR TR2019/05423T patent/TR201905423T4/tr unknown
- 2010-05-19 SM SM20190271T patent/SMT201900271T1/it unknown
- 2010-05-19 WO PCT/US2010/035357 patent/WO2010135396A2/en not_active Ceased
- 2010-05-19 CN CN201610573261.1A patent/CN106176662A/zh active Pending
- 2010-05-19 JP JP2012511072A patent/JP5752677B2/ja active Active
- 2010-05-19 EP EP10720107.1A patent/EP2391355B1/en not_active Revoked
- 2010-05-19 SI SI201031880T patent/SI3351240T1/sl unknown
-
2011
- 2011-08-12 CL CL2011001969A patent/CL2011001969A1/es unknown
- 2011-08-14 IL IL214644A patent/IL214644A/en active IP Right Grant
- 2011-08-15 NI NI201100158A patent/NI201100158A/es unknown
- 2011-08-15 ZA ZA2011/05962A patent/ZA201105962B/en unknown
- 2011-08-16 CR CR20110435A patent/CR20110435A/es unknown
- 2011-09-09 EC EC2011011317A patent/ECSP11011317A/es unknown
- 2011-09-19 CO CO11121706A patent/CO6430422A2/es not_active Application Discontinuation
-
2014
- 2014-07-30 US US14/447,450 patent/US20140336223A1/en not_active Abandoned
-
2015
- 2015-07-03 PH PH12015501523A patent/PH12015501523A1/en unknown
- 2015-10-07 IL IL241949A patent/IL241949A/en active IP Right Grant
- 2015-12-23 US US14/998,262 patent/US9993467B2/en active Active
-
2017
- 2017-02-14 SM SM201700097T patent/SMT201700097B/it unknown
- 2017-02-15 CY CY20171100203T patent/CY1118632T1/el unknown
-
2018
- 2018-05-10 US US15/976,808 patent/US10555939B2/en active Active
-
2019
- 2019-06-17 HR HRP20191094TT patent/HRP20191094T1/hr unknown
- 2019-06-24 CY CY20191100655T patent/CY1122064T1/el unknown
-
2020
- 2020-01-16 US US16/745,240 patent/US20200222382A1/en not_active Abandoned
- 2020-12-08 US US17/115,672 patent/US20210085665A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011134499A (ru) | Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона | |
| JP2015524444A5 (enExample) | ||
| CN108883108B (zh) | 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 | |
| JP2014517050A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2006508953A5 (enExample) | ||
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| JP2014521658A5 (enExample) | ||
| JP2013518124A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2016518388A5 (enExample) | ||
| JP2023541766A5 (enExample) | ||
| JP2021535107A5 (enExample) | ||
| WO2016011254A1 (en) | Combinations of antihistamines and leukotriene antagonists and methods of use thereof | |
| JP2014526508A5 (enExample) | ||
| AR076175A1 (es) | Combinaciones para el tratamiento de enfermedades respiratorias. | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| CN101703553A (zh) | 一种清暑、解毒的食药两用品 | |
| ES2671926T3 (es) | Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico | |
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects | |
| JP2016505050A5 (enExample) | ||
| CA2613617A1 (en) | Compositions and methods for enhancement of sexual function | |
| Siafaka et al. | Current status of pediatric formulations for chronic and acute children’diseases: Applications and future perspectives | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma |